Login to Your Account



Genmab, Novartis Ink Bispecific Antibody Pact for up to $175M

By Cormac Sheridan
Staff Writer

Wednesday, June 6, 2012

Genmab A/S is getting $2 million up front and could receive up to $173 million more in milestone payments on the strength of a deal with Novartis AG on its bispecific antibody technology, DuoBody.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription